Drug Profile
Lanraplenib - Kronos Bio
Alternative Names: GS 9876; GS-SYK; GS-SYK-succinate; lanraplenib succinateLatest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Galapagos NV; Gilead Sciences; Kronos Bio
- Class Amines; Anti-inflammatories; Antirheumatics; Imidazoles; Piperazines; Pyrazines; Small molecules
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- Phase II Cutaneous lupus erythematosus; Lupus nephritis; Rheumatoid arthritis; Sjogren's syndrome
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 18 Dec 2023 Lanraplenib - Kronos Bio is available for licensing as of 18 Dec 2023
- 18 Dec 2023 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain and USA (PO)
- 18 Dec 2023 Adverse events and efficacy data from a phase-I/II trial in Acute myeloid leukaemia released by Kronos Bio